(Q43132960)

14 November 2017

title

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy (English)

1 reference

metastatic renal cell carcinoma

14 November 2017

0 references

1 reference

1 reference

2

Toni K Choueiri

1 reference

14 November 2017

Michael M Vickers

1

1 reference

14 November 2017

Miranda Rogers

3

1 reference

14 November 2017

Andrew Percy

4

1 reference

14 November 2017

Daygen Finch

5

1 reference

14 November 2017

Ivan Zama

6

1 reference

14 November 2017

Tina Cheng

7

1 reference

14 November 2017

Scott North

8

1 reference

14 November 2017

Jennifer J Knox

9

1 reference

14 November 2017

Christian Kollmannsberger

10

1 reference

14 November 2017

David F McDermott

11

1 reference

14 November 2017

Brian I Rini

12

1 reference

14 November 2017

Daniel Y Heng

13

1 reference

14 November 2017

language of work or name

English

0 references

publication date

12 March 2010

1 reference

14 November 2017

1 reference

14 November 2017

volume

76

1 reference

14 November 2017

issue

2

1 reference

14 November 2017

page(s)

430-434

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Sorafenib in advanced clear-cell renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Sequential sorafenib and sunitinib for renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Signaling inhibitors in metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.031

10.1016/J.UROLOGY.2009.12.031

7 January 2021

Identifiers

DOI

1 reference

14 November 2017

1 reference